Highest-materiality recent filing
Forian completes acquisition by 2025 Acquisition Company at $2.17/share; to delist from Nasdaq
6,444,415 shares validly tendered; together with Buyer Parties' 21,991,929 shares, ~91% of outstanding shares.
Forian to be taken private at $2.17/share in all-cash deal led by CEO Max Wygod
All-cash transaction values Forian equity at ~$68M; shareholders receive $2.17/share.
Forian Q4 revenue up 37% but net loss widens; CEO-led buyout proposal in play
Revenue Q4 $8.0M (+37% YoY); full year $30.3M (+50% YoY).
Forian redomiciles from Delaware to Maryland after shareholder approval
Shareholders approved redomiciliation on Jan 8, 2026; 22,312,024 for, 1,620,763 against.
Forian Q3 revenue up 66% to $7.8M; adjusted EBITDA rises 153% to $471K
Revenue $7.76M vs $4.69M YoY; net loss improved to $151K from $205K.
Forian receives go-private proposal from CEO at $2.10/share
CEO Max Wygod leads group proposing to acquire Forian at $2.10 per share for other shareholders.
Director Stanley S. Trotman Jr. resigns from Forian board
Stanley S. Trotman, Jr. resigned from Forian board and all committees effective August 15, 2025.
Forian Q2 revenue $7.5M (+56% YoY); net income $0.2M, EPS $0.01 vs loss
Revenue $7.48M, up 56% from $4.78M in Q2 2024; net income of $0.22M vs loss of $2.55M.
Forian Inc. dismisses CBIZ CPAs, appoints BDO USA as new auditor
On June 26, 2025, the Audit Committee dismissed CBIZ CPAs P.C. as independent registered public accounting firm.
Forian shareholders approve 4M share increase to equity plan at annual meeting
Stockholders approved amendment to 2020 Equity Plan, increasing authorized shares from 6.4M to 10.4M.
Forian Q1 revenue $7.1M (+45% YoY), net loss narrows to $1.1M; FY25 rev guidance $28-30M
Revenue of $7.06M vs $4.88M prior year, a 45% increase driven by acquisitions and new logos.
Forian EVP, General Counsel Edward Spaniel Jr. resigns effective May 23, 2025
Edward Spaniel Jr. resigned as EVP, General Counsel and Corporate Secretary.
Forian replaces Marcum with CBIZ as auditor; two material weaknesses outstanding at Dec 31, 2024
Marcum dismissed as independent auditor effective April 24, 2025; CBIZ engaged for FY 2025.
Forian to restate 2023 and Q3 2024 financials due to revenue recognition error
Audit Committee determined 2023 quarterly/annual and Q3 2024 financials are no longer reliable.
Forian files Kyber Data Science financials showing $12.3M net loss on $4.2M revenue in 2023
Kyber Data Science LLC acquired Oct 31, 2024; audited 2023 revenue $4.16M (99.5% subscription research fees).
Forian Q3 revenue down 12%, net loss of $0.2M; redeems $16M in convertible notes
Revenue of $4.69M, down 12% YoY from $5.35M; net loss of $0.2M vs prior-year income of $4.3M.
Forian acquires Kyber Data Science from TD Cowen to enhance healthcare analytics
Forian (FORA) acquired all equity interests of Kyber Data Science LLC, effective October 31, 2024.
Forian Q2 revenue down 2% YoY, net loss widens to $2.6M; updates FY guidance
Revenue $4.78M vs $4.89M YoY (-2%); net loss $2.55M ($0.08 diluted loss) vs $1.12M ($0.03 loss).
Forian shareholders elect all four Class III directors and ratify Marcum LLP as auditor
Ian Banwell, Adam Dublin, Alyssa Varadhan, Max Wygod elected Class III directors; each received >19.2M votes for.
Forian posts flat Q1 revenue of $4.9M; net loss narrows 46%, adjusted EBITDA turns positive
Revenue $4.9M, unchanged YoY; net loss from continuing ops $1.2M ($0.04/sh) vs $2.2M ($0.08/sh) prior year.
Forian Q4 revenue $5.4M, net income $1.39M; FY 2024 guidance 5-15% revenue growth
Q4 2023 revenue $5.37M (+8% YoY); net income $1.39M vs loss $3.56M prior year.
Forian subsidiary amends data license deal; extends term to 2031, removes revenue share fees
Amendment adds 2014-2023 historical data product for a one-time payment; extends term with two additional renewal options through 2031.
Forian Q3 revenue up 24% to $5.3M; net income from continuing ops $0.16 per share
Revenue $5.35M (+24% YoY); net income from continuing ops $5.45M ($0.16 diluted) vs loss of $2.97M (-$0.09) in Q3 2022.
Forian repurchases 1.6M shares at $2.15 each from Rose Capital affiliates
Repurchased 1,604,676 shares in a privately negotiated transaction at $2.15/share.
Forian Q2 revenue up 36% to $4.9M; net loss narrows to $0.03/sh, Adj EBITDA positive
Revenue $4.9M, up 36% YoY from $3.6M.
Forian receives $5.9M from sale of equity interest in customer; potential $3.6M earnout
Received $5.9M cash from merger of its customer with Vox Merger Sub on July 21, 2023.
Forian stockholders elect three Class II directors, ratify auditors at annual meeting
Elected Mark J. Adler (17.9M for), Jennifer Hajj (18.1M for), Shahir Kassam-Adams (17.8M for) as Class II directors.
Forian Q1 revenue up 38% to $4.9M; continuing ops loss narrows to $2.2M
Revenue $4.87M, +38% YoY; continuing ops net loss $2.25M vs $10.3M loss in prior year.
Forian Q4 revenue up 37% YoY to $7.9M; divests BioTrack for $30M; guides FY2023 rev $20.5-22.5M
Q4 2022 revenue $7.9M (+37% YoY); net loss $3.6M vs $8.0M; adj. EBITDA -$0.9M vs -$4.5M.
Forian sells cannabis software unit BioTrack for $30M; CEO Barton resigns
Sold BioTrack to Alleaves for $30M: $20M cash at close plus $10M in 12 monthly installments.
Forian Q3 revenue $7.2M (+45% YoY); on track to exceed FY2022 revenue guidance
Revenue $7.2M, up 45% YoY and 10% sequentially; net loss $5.1M ($0.16/share) vs $7.0M loss year ago.
Forian Q2 revenue grows 44% to $6.5M; reaffirms FY2022 guidance $25.5-27M
Revenue $6.5M, up 44% YoY from $4.5M; net loss $5.4M ($0.17/sh) vs $7.0M ($0.22/sh).
Forian stockholders approve 2.4M-share increase to 2020 equity plan
Amendment increases plan's authorized shares from 4M to 6.4M; 19.9M for, 0.8M against at June 15 Annual Meeting.
Forian Q1 revenue up 294% to $6.4M; net loss widens to $11.9M; reaffirms FY22 guidance
Revenue $6.4M, +294% YoY; pro forma revenue growth 76% YoY and 11% sequentially.
Forian sets 2022 annual meeting for June 15; proposal deadline April 20
Annual meeting to be held June 15, 2022; record date April 22, 2022.
Forian FY21 revenue $16.9M meets outlook; Q4 revenue +80% pro forma; net loss widens to $0.25/sh
FY21 revenue $16.9M met high end of outlook; pro forma revenue $18.9M increased 53% YoY.
Forian presents at Roth Conference; slide deck furnished, no material new info disclosed
Executive Chairman Max Wygod presents at 34th Annual Roth Conference on March 15, 2022 at 1:30 p.m. PT.
Director Scott Ogur resigns from Forian board effective Dec. 31, 2021
Scott Ogur notified Forian on Dec 28 of resignation as director, effective Dec 31, 2021.
Forian Q3 revenue jumps 62% pro forma to $5.0M; net loss widens to $6.9M
Total revenue $4.96M, +62% pro forma YoY; net loss $6.88M ($0.22 loss per share) vs loss of $1.16M a year ago.
Forian raises $24M via 3.5% convertible notes due 2025; appoints Michael Vesey as CFO
$24M 3.5% convertible notes due 2025, conversion price $11.98, warrants for 20% of principal.
Forian Q2 rev $4.5M (+54% pro forma YoY); net loss $7.1M; guides H2 rev $10.4-10.7M
Revenue $4.5M, pro forma growth 54% YoY and 25% sequential from Q1 2021.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
On April 28, 2025, Edward Spaniel, Jr., Executive Vice President, General Counsel and Corporate Secretary of Forian Inc. (the “Company”), notified the Company of his resignation from all of his positions with the Company and its subsidiaries and affiliates, effective May 23, 2025.
Effective as of February 10 , 2023 , the Board appointed Max C. Wygod as interim Chief Executive Officer and President.
On February 13, 2023, the Company announced that Daniel Barton resigned as the Company’s Chief Executive Officer and President and as a Class II member of the Board of Directors (the “Board”) effective February 10, 2023.
On December 28, 2021, Scott Ogur notified Max Wygod, Executive Chairman of the Board of Directors of Forian Inc. (the “Company”), of his intention to resign as a director of the Company, effective December 31, 2021.
On September 1, 2021, the Company appointed Michael Vesey to the position of Chief Financial Officer, effective September 2, 2021
Max materiality 1.00 · Median 0.65 · Most common event earnings